Cardinal Health stock heads into Q1 test with 2.94 USD EPS view
Published on 10/30/2026 at 10:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors should watch
- Cardinal Health will release fiscal 2027 first-quarter results before the New York market opens on November 5.
- Analysts expect revenue to rise to 66.67 billion US dollars, while the company maintains its full-year adjusted earnings outlook.
- The CVS distribution agreement extension through June 2032 strengthens visibility for a key customer relationship.
Cardinal Health is heading toward its fiscal 2027 first-quarter results with Wall Street focused on whether the healthcare distributor can maintain its recent earnings momentum. Analysts tracked by MarketBeat expect adjusted earnings of 2.94 US dollars per share and revenue of 66.67 billion US dollars for the quarter.
Cardinal Health stock traded at 224.85 euros on Lang & Schwarz at 10:33 a.m. CEST on Friday, October 30; the real-time quote of Cardinal Health stock is available here.
Results set for November 5
Cardinal Health said in an October 1 newsroom announcement that it will publish fiscal 2027 first-quarter results before trading begins on the New York Stock Exchange on Thursday, November 5. The company scheduled its webcast for 8:30 a.m. Eastern Time, giving investors a defined catalyst for the coming week.
The upcoming figures will be measured against a strong prior quarter. MarketBeat reported that Cardinal Health earned 2.91 US dollars per share in the latest quarter, above the 2.42 US-dollar consensus estimate. Revenue reached 63.67 billion US dollars, up 5.8 percent from the year-earlier period, although it was below the 65.15 billion US-dollar estimate cited in the report.
Guidance and customer visibility
Cardinal Health has set fiscal 2027 adjusted earnings guidance at 12.40 to 12.60 US dollars per share. The range represents 13 to 15 percent growth against adjusted fiscal 2026 earnings, excluding the benefit from an IEEPA tariff refund, according to the company's October 1 announcement.
The company also entered a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 30, 2032. The arrangement maintains Cardinal Health's current distribution scope and adds longer-term visibility around a major customer relationship. Management said further updates could come with the first-quarter earnings call.
MarketBeat cited a consensus Moderate Buy rating and an average analyst target of 269.38 US dollars, alongside 16 Buy ratings and three Holds. Those estimates frame investor expectations ahead of the release, but the November report will determine whether current operating performance supports them.
Cardinal Health at a glance
- Company: Cardinal Health
- ISIN: US14149Y1082
- Ticker: CAH
- Home exchange: New York Stock Exchange
- Lang & Schwarz quote: 224.85 euros at 10:33 a.m. CEST on October 30, 2026
- Next report: Fiscal 2027 first-quarter results on November 5, 2026
The broader US equity backdrop remains relevant ahead of the release; investors can follow the S&P 500 market environment.
More earnings coverage and company developments are available in More news and analyses on Cardinal Health stock.
